Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US

Cimerli Biosimilar To Lucentis Captures 38% Of Total Market Volume In December 2023

 
• By David Wallace
  
Graphs and data reflected in eye
Formycon and Coherus see positive data for ranibizumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products